James Duffy is a Senior Director of Drug Discovery at Medicines for Malaria Venture (MMV), Switzerland with 25 years’ experience working in drug discovery. He has a special interest in malaria and other infectious diseases that disproportionately affect vulnerable populations in malaria endemic countries.
Working at MMV, he is part of the efforts to reduce the burden of malaria in disease-endemic countries by discovering, developing and delivering new, effective and affordable antimalarial drugs. His current role is to provide scientific input and strategic leadership to multidisciplinary collaborations with academic, biotechnology and pharmaceutical partners engaged in malaria drug discovery projects.
James obtained his PhD from the University of Sussex (Brighton, UK) and prior to MMV worked at BioFocus (Cambridge, UK) where he was a co-inventor of the FDA approved HDAC inhibitor Belinostat.